LLY — Eli Lilly and Company

Eli Lilly Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue Growth: Q1 2026 revenue increased by 56% compared to Q1 2025, reaching $20.8 billion, driven primarily by strong sales of Semaglutide (Mounjaro) and other key products.
• Gross Margin: Gross margin was 82.6%, a slight decrease from the previous year due to pricing pressures.
• R&D and SG&A Expenses: R&D expenses rose by 28% to support 42 active Phase III programs. SG&A expenses increased by 19% as Lilly invested in promotional activities.
• Non-GAAP EPS: Non-GAAP earnings per share were $8.55, up from $3.34 in Q1 2025, reflecting strong revenue growth.
• Shareholder Returns: $1.5 billion in dividends and $2.4 billion in share repurchases were executed during the quarter.

2. Strategic Updates and Business Highlights

• Product Launch: The new oral GLP-1 therapy, Foundayo, was launched, showing promising early adoption with over 15,000 patients starting treatment within weeks.
• Pipeline Progress: Positive Phase III data were reported for multiple products across therapeutic areas, including obesity, diabetes, and oncology.
• Acquisitions: Lilly announced acquisitions of several companies to enhance its pipeline, including Orna Therapeutics and Ajax Therapeutics.
• Market Expansion: Lilly Employer Connect was launched to facilitate employer access to obesity medications, and the Medicare GLP-1 bridge program was extended.

3. Forward Guidance and Outlook

• Revenue Guidance: Full-year revenue is now expected between $82 billion and $85 billion, reflecting strong underlying performance, particularly from Mounjaro and Semaglutide.
• EPS Guidance: Non-GAAP EPS is projected to be between $35.50 and $37.00, an increase from previous estimates.
• Market Dynamics: Despite pricing headwinds expected to impact revenue in the low to mid-teens, Lilly anticipates continued strong growth across its product portfolio.

4. Bad News, Challenges, or Points of Concern

• Pricing Pressure: U.S. prices for some products have declined, impacting margins, with a noted 10% decline in U.S. pricing excluding adjustments.
• Market Competition: The entry of generic competitors, particularly in the obesity market, poses a risk, although initial data suggests it may stimulate overall market growth.
• Access Challenges: While the Medicare bridge program is beneficial, the long-term sustainability of coverage for obesity medications remains uncertain.

5. Notable Q&A Insights

• Pricing Dynamics: CEO Dave Ricks emphasized that the obesity market operates differently than traditional pharmaceuticals, with volume growth often outpacing price reductions.
• International Growth: Strong international performance for Mounjaro was highlighted, with expectations for continued market share gains despite the presence of generics.
• Employer Connect Program: The initiative aims to increase employer coverage for obesity treatments, with gradual adoption expected as more data on health benefits become available.
• Foundayo Launch Confidence: Early indicators for Foundayo's launch are positive, with a focus on educating healthcare providers and increasing consumer awareness before a full-scale marketing push.

Overall, Eli Lilly's Q1 2026 results reflect robust growth and strategic advancements, particularly in the obesity treatment space, while navigating challenges related to pricing and market competition.